ArticleAesthetic plastic surgery2026
A Three-Point, Low-Dose, Artery-Targeted Botulinum Toxin Treatment for Chronic Migraine: A Randomized, Double-Blind, Contralateral-Controlled Trial.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMigraine is a prevalent neurovascular disorder with complex neural and vascular mechanisms. Botulinum toxin type A (BoNT-A) is an established preventive treatment for chronic migraine, yet its vascular effects remain unclear. This study investigated whether targeted BoNT-A injections along migraine-related arteries reduce headache intensity and alter vascular diameter. MATERIALS AND
methodsIn this prospective, randomized, double-blind, controlled trial, 23 adults with chronic migraine received BoNT-A injections on one side of the head and saline on the contralateral side. Three injection points were placed along the superficial temporal artery (STA). Ultrasound measurements of the STA (proximal and distal) and supraorbital (SO) arteries were obtained at baseline, 1 h, 2 weeks, and 2 months. Pain intensity was assessed using a 10-point Visual Analogue Scale (VAS).
resultsMean VAS scores on the BoNT-A-treated side decreased significantly from 8.7 ± 1.46 at baseline to 2.65 ± 1.15 at 2 months (p < 0.001). No significant vascular diameter changes were detected in the STA or SO arteries between treatment and control sides (p < 0.05). No adverse events were reported.
conclusionArtery-targeted BoNT-A injections produced a significant reduction in migraine pain without measurable arterial dilation, suggesting that therapeutic effects are mediated primarily through neural and neurochemical modulation rather than vascular diameter changes. This low-dose, artery-focused approach may represent a safe, efficient refinement of current migraine injection protocols. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42640284What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.